NCT05625750 Observational Study About Patients Diagnosed With NAFLD
| NCT ID | NCT05625750 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xiangya Hospital of Central South University |
| Condition | Nonalcoholic Fatty Liver Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2022-04-27 |
| Primary Completion | 2025-04-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2022-04-27 with a primary completion date of 2025-04-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome. The largest study to date using magnetic resonance spectroscopy to quantify liver triglyceride (TG) content showed that approximately 33% of individuals have hepatic steatosis. NAFLD encompasses a continuum of histological findings that starts with steatosis that can progress to nonalcoholic steatohepatitis (NASH), which is characterized by inflammation and cell death, and eventually cirrhosis. Given the large number of individuals afflicted with this condition, there is a clear need to develop effective and safe therapies to treat NAFLD.
Eligibility Criteria
Inclusion Criteria: 1\. patients diagnosed with nonalcoholic fatty liver disease Exclusion Criteria: 1. patients suspected of excessive alcohol consumption 2. malignant tumors, dementia, active tuberculosis, AIDS, organ failure, pregnancy or breastfeeding, etc cannot cooperate with the investigation 3. incomplete data such as HBV serological results and abdominal ultrasound results 4. patients who refuse to sign informed consent
Contact & Investigator
Yan Huang
STUDY DIRECTOR
Xiangya Hospital of Central South University
Frequently Asked Questions
Who can join the NCT05625750 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Nonalcoholic Fatty Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05625750 currently recruiting?
Yes, NCT05625750 is actively recruiting participants. Contact the research team at ganrankedrhyan@163.com for enrollment information.
Where is the NCT05625750 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT05625750 clinical trial?
NCT05625750 is sponsored by Xiangya Hospital of Central South University. The principal investigator is Yan Huang at Xiangya Hospital of Central South University. The trial plans to enroll 500 participants.